Recent advances in the CLL treatment landscape

In this video, Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, shares some insights into the treatment landscape of chronic lymphocytic leukemia (CLL), highlighting the important role of Bruton's tyrosine kinase (BTK) inhibitors and venetoclax, as well as emerging treatment options for patients who progress after these therapies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.